DSS (DSS) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
13 Jun, 2025Executive summary
Revenue for Q2 2024 was $4.2M, down 42% from Q2 2023, with a net loss of $5.0M, a significant improvement from a $37.7M loss in Q2 2023, mainly due to the deconsolidation of SHRG.
Six-month revenue fell 58% year-over-year to $8.1M, with a net loss of $10.1M versus $46.4M in the prior year period.
Major revenue declines were seen in rental income (down 74%) and direct marketing (down 100%) due to tenant nonpayment and the SHRG deconsolidation.
Cost reductions in SG&A, professional fees, and R&D were driven by the SHRG deconsolidation and cost-cutting measures.
Financial highlights
Q2 2024 revenue: $4.2M (Q2 2023: $7.2M); six-month revenue: $8.1M (2023: $19.1M).
Q2 2024 net loss: $5.0M (Q2 2023: $37.7M); six-month net loss: $10.1M (2023: $46.4M).
Cash and cash equivalents at June 30, 2024: $10.7M; marketable securities: $9.6M.
Total assets: $144.4M; total liabilities: $71.3M; stockholders’ equity: $55.2M.
Operating cash outflow for six months: $5.6M, improved from $19.7M outflow in 2023.
Outlook and guidance
Management believes current cash and marketable securities, plus planned asset sales, are sufficient to fund operations for at least 12 months.
Ongoing cost reductions and asset sales (notably AMRE LifeCare and Winter Haven) are expected to improve liquidity.
Latest events from DSS
- $10M shelf registration supports a multi-division growth strategy and future public offerings.DSS
Registration Filing16 Dec 2025 - Diversified issuer seeks $10M via shelf registration to fund growth across multiple business lines.DSS
Registration Filing16 Dec 2025 - Shareholders will elect directors, ratify the auditor, and vote on executive pay, with major ownership concentrated.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, and executive pay, with strong board oversight.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, compensation, and major shareholder control.DSS
Proxy Filing2 Dec 2025 - Revenue up 22% year-over-year, net loss narrows, but going concern risk persists.DSS
Q3 202514 Nov 2025 - Revenue up 27% and net loss narrowed, but going concern risk persists.DSS
Q2 202514 Aug 2025 - Q3 revenue rose 34% year-over-year, but nine-month revenue fell 28% as net losses narrowed.DSS
Q3 202413 Jun 2025 - DSS, Inc. posted a $46.9M net loss in 2024, but completed the Impact BioMedical IPO.DSS
Q4 20249 Jun 2025